Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New methods needed for preclinical tests, scientists say
rat
"Research and development effort is often wasted because of the poor reliability of animal-based methods."
Calls for non-animal models following publication of a new scientific paper

FRAME - the Fund for the Replacement of Animals in Medical Experiments - is calling for more collaboration between organisations, government and the pharmaceutical industry following a new investigation of preclinical drug trials.

Scientific papers covering more than 2,300 substances that were tested on rats, mice and rabbits were analysed to measure the likelihood that chemicals showing no adverse reactions in trials using laboratory animals would behave the same way in humans.

The results, says director of FRAME Alternatives Laboratory Dr Andrew Bennett, suggest large numbers of compounds that are functional in animals show little potency in humans, while others that show no adverse reactions in animals later prove harmful in human trials.

Dr Bennett says the paper, published in FRAME's scientific journal ATLA, highlights the need for more relevant non-animal tests but he believes they can only be found if all those involved work together to look for them.

"Toxicity data from animal studies can be seriously misleading but it is no good just saying that animal tests don't work - we have to find methods that can identify potential risks and benefits. There are major issues for companies in the pharmaceutical sector. Research and development effort is often wasted because of the poor reliability of animal-based methods. If we are to find useful, safe drugs in the future it is vital that all interested parties work together to find valid, non-animal methods that will identify them."

Preclinical tests require the use of two species, usually one rodent (rat or mouse) and one non-rodent (often dogs) before drugs enter clinical trials in humans. The second species is intended to identify those substances harmful to humans that were missed by the rodent tests.

This latest study was carried out by the same team who investigated the use of dogs in human drugs tests last year, that concluded that animal results are inconsistent. The latest statistical analysis of results from rats, mice and rabbits supported those findings, although it is in part to be expected as drugs now being developed are increasingly aimed at specific human cell responses.

FRAME was established in 1969 to promote the concept of alternatives to laboratory animal use in medical research and toxicity testing. The charity is dedicated to developing and validating alternative methods, and working actively with all interested parties.

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.